Phio Pharmaceuticals(PHIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PHIO Phio Pharmaceuticals

Closed Good Friday 04-17 16:00:00 EDT

2.73

+0.03

+1.11%

盘后2.77

+0.04+1.44%

19:59 EDT

High3.05	Low2.70	Vol1.64M
Open2.71	D1 Closing2.70	Amplitude12.94%
Mkt Cap13.04M	Tradable Cap13.03M	Total Shares4.78M
T/O4.65M	T/O Rate34.28%	Tradable Shares4.77M
P/B2.76	ROE-114.83%	EPS-9.08
52wk High9.79	52wk Low0.9657	P/E-0.30
Dividend0.00	Div.Yield0.00	ROA-61.14%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"PHIO","market":"US","secType":"STK","nameCN":"Phio Pharmaceuticals","latestPrice":2.73,"timestamp":1744920000000,"preClose":2.7,"halted":0,"volume":1636813,"hourTrading":{"tag":"盘后","latestPrice":2.7693,"preClose":2.73,"latestTime":"19:59 EDT","volume":38434,"amount":104763.7837,"timestamp":1744934399148},"delay":0,"floatShares":4774506,"shares":4778154,"eps":-9.079757,"marketStatus":"Closed Good Friday","change":0.03,"latestTime":"04-17 16:00:00 EDT","open":2.71,"high":3.0494,"low":2.7,"amount":4651428.7287922,"amplitude":0.129407,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-9.079757,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":2.7,"preHourTrading":{"tag":"盘前","latestPrice":2.7098,"preClose":2.7,"latestTime":"09:29 EDT","volume":65981,"amount":179833.392873,"timestamp":1744896598235},"postHourTrading":{"tag":"盘后","latestPrice":2.7693,"preClose":2.73,"latestTime":"19:59 EDT","volume":38434,"amount":104763.7837,"timestamp":1744934399148},"volumeRatio":0.4501318979425065,"impliedVol":2.2675,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/PHIO","defaultTab":"news","newsList":[{"id":"2526511532","title":"PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2526511532","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526511532?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 22:53","pubTimestamp":1744296780,"startTime":"0","endTime":"0","summary":"Shares of Phio Pharmaceuticals PHIO rallied 52.5% on Wednesday after the company announced that the Safety Monitoring Committee  has recommended dose escalation in an early-stage study of the company’s investigational skin cancer candidate, PH-762.PH-762 is Phio Pharmaceuticals’ lead and only clinical-stage candidate, which is being developed leveraging its proprietary IntasylsiRNA gene silencing technology to eliminate cancer. The phase Ib dose escalation study is evaluating the safety and tolerability of neoadjuvant use of intratumoral PH-762 for cutaneous squamous cell carcinoma, melanoma or Merkel cell carcinoma.The SMC’s decision allowing escalation to the next dose concentration was based on the favorable safety profile of the drug observed in the third cohort of the phase Ib study, which enrolled three patients with cutaneous squamous cell carcinoma. In these patients, injections were well tolerated, with no serious adverse events or dose-limiting toxicities. Pathology results a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/phio-stock-soars-safety-panel-145300505.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BAYRY","SMC","ADMA","BK4144","DVAX","PHIO","BK4139"],"gpt_icon":0},{"id":"2526539428","title":"Crude Oil Down 4%; Neogen Shares Plunge After Q3 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2526539428","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526539428?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 00:06","pubTimestamp":1744214792,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/04/44717350/crude-oil-down-4-neogen-shares-plunge-after-q3-results","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","BE","NEOG","QID","BK4541","LU0444973449.USD","VINC","QLD","NQmain","LU2249611893.SGD","BK4212","LU0823414478.USD","LU1642822529.SGD","LU0823414551.USD","SQQQ","MNQmain","LU2357125470.USD","PSQ","PHIO","LU2211817866.USD","BK4585","BK4182",".IXIC","BK4139","BK4588","LU0957808578.USD","LU1815336760.USD","TQQQ","USAW.SI","LU0444971666.USD","SMPL","USJW.SI","XXII","BK4075","LU0476273544.USD","LU2506951792.HKD","NVIW.SI","TSYW.SI","VERO","LU2294711713.HKD","BK4082"],"gpt_icon":1},{"id":"2526365606","title":"Phio Pharmaceuticals Potential Skin Cancer Treatment Recommended for Dose Escalation","url":"https://stock-news.laohu8.com/highlight/detail?id=2526365606","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526365606?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 20:23","pubTimestamp":1744201406,"startTime":"0","endTime":"0","summary":"Phio Pharmaceuticals  said Wednesday the Safety Monitoring Committee has recommended dose escalation in its phase 1b clinical trial of PH-762 as a potential neoadjuvant treatment for cutaneous squamous cell carcinoma, melanoma or Merkel cell carcinoma.The recommendation came after seven patients in the study with cutaneous carcinoma showed at least 90% tumor clearance after 36 days, the company said.Shares of the biotech firm were up more than 20% in recent premarket activity Wednesday.Price: 1.22, Change: +0.21, Percent Change: +20.76","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PHIO","BK4139"],"gpt_icon":0},{"id":"2526887363","title":"Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort","url":"https://stock-news.laohu8.com/highlight/detail?id=2526887363","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526887363?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 19:45","pubTimestamp":1744199100,"startTime":"0","endTime":"0","summary":"-Phio's lead clinical siRNA compound PH-762 demonstrates supportive safety profile in third cohort, permitting escalation in next dose concentration. Marlborough, Massachusetts-- - Phio Pharmaceuticals Corp.  is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL siRNA gene silencing technology to eliminate cancer. Phio announced today that the Safety Monitoring Committee  recommended dose escalation in Phio's Phase 1b clinical trial  for Phio's lead product candidate, PH-762.Phio's Phase 1b clinical trial is a multi-center, dose-escalating trial designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma. This trial assesses the tumor response and determines the recommended dose for further study of PH-762. In the third cohort of this trial, three patients with cutaneous squamous cell carcinoma were enrolled. For these patients, inj","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/phio-pharmaceuticals-announces-positive-safety-114500926.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/phio-pharmaceuticals-announces-positive-safety-114500926.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SMC","LU0211331839.USD","LU0256863902.USD","BK4161","BK4139","BK4144","LU0070302665.USD","BK4580","LU0256863811.USD","LU0320765489.SGD","LU0208291251.USD","LU0417517546.SGD","BK4585","LU1989772840.SGD","BK4588","PHIO","PH","LU1989772923.USD"],"gpt_icon":0},{"id":"2525896512","title":"Phio Pharmaceuticals Price Target Maintained With a $4.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2525896512","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525896512?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 19:51","pubTimestamp":1744113060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PHIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 08, 2025 07:51 ET (11:51 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHIO"],"gpt_icon":0},{"id":"2524256808","title":"Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894","url":"https://stock-news.laohu8.com/highlight/detail?id=2524256808","media":"Newsfile","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524256808?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 19:45","pubTimestamp":1743680700,"startTime":"0","endTime":"0","summary":"To be presented at 11th Annual Immunotherapy of Cancer  Conference in Munich, Germany. Marlborough, Massachusetts-- - Phio Pharmaceuticals Corp.  is a clinical-stage siRNA biotechnology company developing therapeutics using its proprietary INTASYL gene silencing technology to eliminate cancer. Phio today announced that podium presentations will be given on its two lead INTASYL product candidates, PH-762 and PH-894.The ITOC conference provides a unique platform for the exchange of latest findings in immunotherapy of cancer to advance oncology drug development and delivery.Melissa Maxwell, Phio's Director of Research and Program Management, was awarded two speaker presentations, as follows:. Plenary Session 3: New Targets and New Leads Date and Time: April 3, 2025, 16.30 - 16.45 PM . This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-Looking statements can be identified by words such as \"intends,\" \"be","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/phio-pharmaceuticals-announces-podium-presentations-114500937.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/phio-pharmaceuticals-announces-podium-presentations-114500937.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0208291251.USD","LU0256863811.USD","LU0070302665.USD","LU0211331839.USD","LU1989772840.SGD","PHIO","BK4588","BK4580","LU0256863902.USD","LU1989772923.USD","LU0320765489.SGD","PH","BK4161","BK4585","BK4139","LU0417517546.SGD"],"gpt_icon":0},{"id":"2524216942","title":"Phio Pharmaceuticals Corp reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2524216942","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524216942?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 17:07","pubTimestamp":1743498428,"startTime":"0","endTime":"0","summary":"Phio Pharmaceuticals Corp reports results for the quarter ended December 31 - Earnings SummaryPhio Pharmaceuticals Corp PHIO.OQ reported a quarterly adjusted loss of 85 cents per share for the quarter","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nL5N3QF0I7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHIO"],"gpt_icon":0},{"id":"2523355376","title":"Phio Pharmaceuticals Corp  expected to post a loss of $1.23 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2523355376","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523355376?lang=en_us&edition=full_marsco","pubTime":"2025-03-29 04:58","pubTimestamp":1743195485,"startTime":"0","endTime":"0","summary":"Phio Pharmaceuticals Corp  expected to post a loss of $1.23 a share - Earnings Preview Phio Pharmaceuticals Corp PHIO.OQ PHIO.O is expected to report resultson March 31 (estimated) for the period endi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nL5N3QB1U0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHIO"],"gpt_icon":0},{"id":"2518753228","title":"American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2518753228","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518753228?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 19:45","pubTimestamp":1741607100,"startTime":"0","endTime":"0","summary":"Interim Results from clinical study for cutaneous carcinomas presented at Late-Breaking Research Session. Marlborough, Massachusetts-- - Phio Pharmaceuticals Corp.  is a clinical-stage biotechnology company developing therapeutics that use its INTASYL siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio today announced that a podium presentation addressing its lead product candidate, PH-762, was given in the Academy's Late-Breaking Research session. The Late-Breaking Research session includes oral presentations of the top-scoring abstracts that address common and complex dermatological conditions.Mary Spellman, MD, FAAD, presented \"PD-1 Directed Intratumoral Immunotherapy for Cutaneous Carcinomas: Interim Results from an Ongoing Study of INTASYL PH-762\" which provided details on the design and progress of Phio's ongoing open-label Phase 1b clinical study , to evaluate the safety and tolerability of neoadjuvant use of intr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/american-academy-dermatology-awards-podium-114500793.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/american-academy-dermatology-awards-podium-114500793.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","PHIO","AFG","BK4117","BK4107"],"gpt_icon":0},{"id":"2517916229","title":"Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2517916229","media":"Newsfile","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517916229?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 20:45","pubTimestamp":1741178700,"startTime":"0","endTime":"0","summary":"Marlborough, Massachusetts-- - Phio Pharmaceuticals Corp.  is a clinical-stage biotechnology company developing therapeutics that use its INTASYL siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today that it has fulfilled the required enrollment for safety in its third dose cohort in its Phase 1b dose escalating clinical study for their lead compound PH-762. The company plans to initiate screening of the fourth dose cohort in early April.About Phio Pharmaceuticals Corp.Phio Pharmaceuticals Corp.  is a clinical-stage biotechnology company advancing its proprietary INTASYL siRNA gene silencing technology to eliminate cancer. INTASYL can target and silence virtually any gene with high degree of specificity across a wide range of cell types and tissues. INTASYL is designed to enhance the ability of immune cells to more effectively kill tumor cells. INTASYL has also demonstrated enhancement to adoptive cell ther","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/phio-pharmaceuticals-announces-completion-enrollment-124500433.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/phio-pharmaceuticals-announces-completion-enrollment-124500433.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4580","BK4588","PH","BK4161","LU1989772840.SGD","LU0256863902.USD","LU0417517546.SGD","BK4585","LU0256863811.USD","LU0208291251.USD","LU0070302665.USD","LU1989772923.USD","PHIO","LU0211331839.USD","LU0320765489.SGD"],"gpt_icon":0},{"id":"2514898837","title":"Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series","url":"https://stock-news.laohu8.com/highlight/detail?id=2514898837","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514898837?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 20:45","pubTimestamp":1740573900,"startTime":"0","endTime":"0","summary":"Registration Link for Presentation and live Q&A to take place, Wednesday March 5, 2025 at 12:00 pm EST. Marlborough, Massachusetts-- - Phio Pharmaceuticals Corp.  a clinical-stage biotechnology company developing therapeutics that use its INTASYL siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present its proprietary INTASYL siRNA technology and its on-going clinical trial with lead compound PH-762 for treatment of skin cancers.\"We invite all stakeholders, investors, and other individual followers to register and attend this event to learn about Phio Pharmaceuticals and our pursuit of cancer free futures to improve the lives of patients using our Intasyl technology,\" stated Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/phio-pharmaceuticals-announces-participation-renmark-124500702.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/phio-pharmaceuticals-announces-participation-renmark-124500702.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","PHIO"],"gpt_icon":0},{"id":"2512482347","title":"Phio Pharmaceuticals Price Target Maintained With a $4.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2512482347","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512482347?lang=en_us&edition=full_marsco","pubTime":"2025-02-20 00:39","pubTimestamp":1739983140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PHIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 19, 2025 11:39 ET (16:39 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHIO"],"gpt_icon":0},{"id":"2512488143","title":"Positive Outlook for Phio Pharmaceuticals: Promising Clinical Results and Innovative Technology Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2512488143","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512488143?lang=en_us&edition=full_marsco","pubTime":"2025-02-19 22:35","pubTimestamp":1739975722,"startTime":"0","endTime":"0","summary":"Analyst Vernon Bernardino of H.C. Wainwright reiterated a Buy rating on Phio Pharmaceuticals (PHIO – Research Report), with a price target of $4.00...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positive-outlook-for-phio-pharmaceuticals-promising-clinical-results-and-innovative-technology-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positive-outlook-for-phio-pharmaceuticals-promising-clinical-results-and-innovative-technology-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PHIO"],"gpt_icon":0},{"id":"2508102461","title":"Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series","url":"https://stock-news.laohu8.com/highlight/detail?id=2508102461","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508102461?lang=en_us&edition=full_marsco","pubTime":"2025-02-03 20:45","pubTimestamp":1738586700,"startTime":"0","endTime":"0","summary":"Registration Link for Presentation and live Q&A to take place, Tuesday February 4, 2025 at 2:00 pm EST. Marlborough, Massachusetts-- - Phio Pharmaceuticals Corp.  is a clinical-stage biotechnology company developing therapeutics that use its INTASYL siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present its proprietary INTASYL siRNA technology and its on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Phio is committed to the pursuit of cancer free futures to improve the lives of patients by utilizing its Intasyl technology.Phio Pharmaceuticals welcomes stakeholders, investors, and other individual followers to register and attend this live event.Renmark Virtual Non-Deal Roadshow: NASDAQ - PHIO | Event Registration | Renmark Financial Communications. This press release contains forward-lo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/phio-pharmaceuticals-announces-participation-renmark-124500877.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/phio-pharmaceuticals-announces-participation-renmark-124500877.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SQQQ","TSYW.SI","NVIW.SI","PSQ","MNQmain","USAW.SI","PHIO","QID","TQQQ","USJW.SI",".IXIC","NQmain","QLD"],"gpt_icon":1},{"id":"2505746850","title":"Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series","url":"https://stock-news.laohu8.com/highlight/detail?id=2505746850","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505746850?lang=en_us&edition=full_marsco","pubTime":"2025-01-22 20:00","pubTimestamp":1737547200,"startTime":"0","endTime":"0","summary":"Registration Link for Presentation and live Q&A to take place, Wednesday January 29, 2025 at 2:00 pm EST. Marlborough, Massachusetts-- - Phio Pharmaceuticals Corp.  is a clinical-stage biotechnology company developing therapeutics that use its INTASYL siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present its proprietary INTASYL siRNA technology and an update on its on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Phio is committed to the pursuit of cancer free futures to improve the lives of patients by utilizing its Intasyl technology.Phio Pharmaceuticals welcomes stakeholders, investors, and other individual followers to register and attend this live event.Renmark Virtual Non-Deal Roadshow: NASDAQ - PHIO | Event Registration | Renmark Financial Communications. This press release cont","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/phio-pharmaceuticals-participate-renmark-financial-120000201.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/phio-pharmaceuticals-participate-renmark-financial-120000201.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","QLD","USJW.SI","TSYW.SI",".IXIC","NQmain","TQQQ","USAW.SI","MNQmain","NVIW.SI","QID","PHIO","PSQ","SQQQ"],"gpt_icon":1},{"id":"2505735951","title":"Phio Files Registration Statement for Share Resale","url":"https://stock-news.laohu8.com/highlight/detail?id=2505735951","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505735951?lang=en_us&edition=full_marsco","pubTime":"2025-01-22 06:48","pubTimestamp":1737499726,"startTime":"0","endTime":"0","summary":"Phio Pharmaceuticals  late Tuesday filed a registration statement with US Securities Exchange Commission for the resale of up to about 5.9 million shares by its shareholders.The prospectus coverage includes up to 437,192 shares issuable on exercise of series E warrants and up to 240,000 shares on exercise of series F warrants, according to the filing.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PHIO","BK4139"],"gpt_icon":0},{"id":"2505787058","title":"Phio Pharmaceuticals files to sell 5.93M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2505787058","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505787058?lang=en_us&edition=full_marsco","pubTime":"2025-01-22 05:45","pubTimestamp":1737495915,"startTime":"0","endTime":"0","summary":"16:41 EST Phio Pharmaceuticals (PHIO) files to sell 5.93M shares of common stock for holders Published first on TheFly – the ultimate source for re...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/phio-pharmaceuticals-files-to-sell-5-93m-shares-of-common-stock-for-holders?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/phio-pharmaceuticals-files-to-sell-5-93m-shares-of-common-stock-for-holders?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PHIO"],"gpt_icon":0},{"id":"2505155787","title":"Phio Pharmaceuticals Corp Files for Offering of up to 5.93 Mln Common Shares by the Selling Stockholders - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2505155787","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505155787?lang=en_us&edition=full_marsco","pubTime":"2025-01-22 05:40","pubTimestamp":1737495656,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250121:nFWN3OH20C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PHIO","BK4139"],"gpt_icon":0},{"id":"2505959782","title":"Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2505959782","media":"Newsfile","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505959782?lang=en_us&edition=full_marsco","pubTime":"2025-01-22 05:15","pubTimestamp":1737494100,"startTime":"0","endTime":"0","summary":"Raised approximately $12.08 million in gross proceeds since beginning of December 2024. Proceeds intended to be directed for development costs to be incurred in connection with PH-762 clinical activities. The aggregate gross proceeds to the Company from this financing were $1.83 million, before deducting the placement agent fees and other offering expenses payable by the Company. The total gross proceeds raised by the Company in registered direct offerings and concurrent private placements since the beginning of December 2024 are approximately $9.15 million, before deducting placement agent fees and other offering expenses payable by the Company. Additional gross proceeds of approximately $2.9 million were raised from the exercise of warrants previously issued on July 12, 2024 having an exercise price of $5.45 per share.The shares of common stock issued in the January 16, 2024 financing  were offered by the Company pursuant to a \"shelf\" registration statement on Form S-3  filed with th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/phio-pharmaceuticals-announces-closing-1-211500028.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/phio-pharmaceuticals-announces-closing-1-211500028.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NDAQ","USAW.SI","LU2095319765.USD","IE00BGHQF748.EUR","QLD","TQQQ","IE00B64PRP62.GBP","IE00BKPKM429.USD","PHIO","BK4139","BK4112","PSQ","NVIW.SI","IE00B3QW5Z07.USD","TSYW.SI","QID","BK4585","USJW.SI","LU2210149790.SGD","NQmain","SQQQ","BK4588","LU2210150020.SGD","MNQmain",".IXIC"],"gpt_icon":1},{"id":"2504294659","title":"Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2504294659","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504294659?lang=en_us&edition=full_marsco","pubTime":"2025-01-17 02:00","pubTimestamp":1737050400,"startTime":"0","endTime":"0","summary":"Marlborough, Massachusetts-- - Phio Pharmaceuticals Corp. , a clinical-stage biotechnology company that develops therapeutics using its INTASYL siRNA gene silencing technology to make the body's immune cells more effective in killing cancer cells, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 610,000 shares of its common stock at a purchase price of $3.00 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue short-term unregistered warrants to purchase up to an aggregate of 1,220,000 shares of common stock. The short-term warrants will have an exercise price of $3.00 per share, will be exercisable upon issuance and expire twenty-four months following the date of issuance. The closing of the offering is expected to occur on or about January 17, 2025, subject to the satisfaction of customary closing conditions.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/phio-pharmaceuticals-announces-1-83-180000477.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/phio-pharmaceuticals-announces-1-83-180000477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2095319765.USD","BK4112","BK4588","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","LU2210150020.SGD",".IXIC","LU2210149790.SGD","PHIO","IE00BKPKM429.USD","NDAQ","BK4139","IE00BGHQF748.EUR","BK4585"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.phiopharma.com","stockEarnings":[{"period":"1week","weight":0.6545},{"period":"1month","weight":0.964},{"period":"3month","weight":-0.0144},{"period":"6month","weight":-0.0619},{"period":"1year","weight":-0.5326},{"period":"ytd","weight":0.5167}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":-0.043516},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.058261},{"month":3,"riseRate":0.416667,"avgChangeRate":-0.080913},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.019306},{"month":5,"riseRate":0.272727,"avgChangeRate":-0.038426},{"month":6,"riseRate":0.454545,"avgChangeRate":-0.020605},{"month":7,"riseRate":0.363636,"avgChangeRate":-0.103097},{"month":8,"riseRate":0.272727,"avgChangeRate":-0.030187},{"month":9,"riseRate":0.090909,"avgChangeRate":-0.131629},{"month":10,"riseRate":0.272727,"avgChangeRate":-0.131123},{"month":11,"riseRate":0.363636,"avgChangeRate":-0.063336},{"month":12,"riseRate":0.181818,"avgChangeRate":-0.144776}],"exchange":"NASDAQ","name":"Phio Pharmaceuticals","nameEN":"Phio Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Phio Pharmaceuticals(PHIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Phio Pharmaceuticals(PHIO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Phio Pharmaceuticals,PHIO,Phio Pharmaceuticals股票,Phio Pharmaceuticals股票老虎,Phio Pharmaceuticals股票老虎国际,Phio Pharmaceuticals行情,Phio Pharmaceuticals股票行情,Phio Pharmaceuticals股价,Phio Pharmaceuticals股市,Phio Pharmaceuticals股票价格,Phio Pharmaceuticals股票交易,Phio Pharmaceuticals股票购买,Phio Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Phio Pharmaceuticals(PHIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Phio Pharmaceuticals(PHIO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction